20SMA going to hit over 50SMA soon!

yes, cheap!

still got next week to go!

exercise price is 0.18!

u will get 0.30 if Hovid masuk PN-17!

love2trade, then u slow slow wait 50 years!

http://www.btimes.com.my/Current_News/BTIMES/articles/10HOVID/Article/

Wei Xin: yes, it's growing and back to profit now!

Still a good price to buy in, buy before it's too late! :)

Can see 10,000 units being sapu-ed last minute on Friday! Meaning Monday breakout is imminent!

Hovid - Boost From Drug Patent Expiry

Author: kiasutrader | Publish date: Fri, 10 Jan 16:14

Hovid sees great potential in the coming years. It recently launched generic versions of drugs which went off patent 2011. An estimated USD15bn in medicines have gone off patent in 2013, boosting its potential new products pipeline. Plans are already in place to raise production capacity by 30% in 2014. We value the stock at 42 sen, pegged to 17x CY14F fully diluted EPS – an 18% upside.

We hosted a corporate luncheon with Hovid for our clients in Dec 2013. Management was represented by CFO and executive director Mr Andrew Goh. Given the current trend of patent protection expiry for major “innovator drugs”, management was upbeat on Hovid’s prospects as a generic drug manufacturer. We concur with this view. The company is now ramping up capacity to capitalise on this trend.
Tasty takeaways from the luncheon. Among the notable takeaways from the luncheon were the fact that Hovid: i) recently launched generic versions of two drugs whose patent protection recently expired – these medicines generated a combined USD9.7bn annually in global sales before their patents ended, and ii) is working on a further six generic versions of major drugs in 2014. Based on estimates, there at least 17 drugs – worth USD15bn in total global sales – whose patents expired last year.
3-year (FY13-16) net profit CAGR of 21.9%. Hovid plans to launch 10-12 new products annually going forward. To support its ambitions, the company is: i) expanding capacity at its tablet and capsule plant this year with a planned initial “30% increase”, ii) setting up its own bioequivalence test centre for new generic drugs, and iii) building a new central warehouse to better manage the increase in inventory.
MYR0.42 FV, 18% upside. We value Hovid at 17x CY14F fully diluted EPS, a discount to global peers average of 18x 2014 earnings. That said, while there is a substantial warrant base, we do not think conversions are likely at this juncture. Pre-dilution, Hovid’s share price would be 61 sen at 17x P/E. We like the company for its: i) 21.9% 3-year earnings CAGR, ii) strong exposure to the export market – ie wellpositioned to benefit from further USD/MYR appreciation, iii) net cash position, and iv) decent 15% ROE. This stock is Not Rated.

Profit taking in place, today is T+4

buy! It will hit above 0.20 before Chinese New Year

chart normally not bluff people, i believe in technical too besides fundamental!

i work in this company before...previously the company did not perform, keep losing $$$

good!

Highlights / Stock Picks of the Day - Hovid Berhad (HOVID) – Not Rated

Author: kiasutrader | Publish date: Thu, 9 Jan 09:45
Market expectations that the earnings of small cap drug manufacturers are recovering and HOVID is one of the beneficiaries of the latest round of National Key Economic Area (NKEA) Healthcare initiatives managed to spark investors’ interest in the stock over past few days. In fact, the accumulating buying interest causes its share price to break out from the “Bullish Flag” chart pattern. Key momentum indicators also switching from bearish to bullish mode, with the MACD just crossed over the Signal line. All signals have led us to believe that HOVID is poised for another upwards movement, making its way up to RM0.40. Traders looking to buy into the stock should aim to lock in their gains 3 bids below this targeted level (RM0.385). Meanwhile, a protective stop-loss should also be placed just below the Flag support at RM0.33.

Source: Kenanga

Sell car sell house buy buy! :)

I am back, run for your life! Redtone will drop tomorrow after failing to secure the DTTB! As I mentioned earlier, they failed the bid!

It can go 0.50 unless news come out "Syed Mokhtar target Hovid for pharmaceuticals"

0.50 next week, dun con us man!

But I still could not understand, if Syed Mokhtar rumour takeover, should up more...but this one like market up stock up only!

I was curious and checked with my remisier as well! He also alerted that Syed Mokhtar becoming substantial shareholder. Wow! Spread news ady!

wow! Thanks for the new Tommylim!

They are accumulating as well, so I think Hovid will resume uptrend again!

yes, this rumours might be true!

It had appointed 2 new directors I think to strengthen the company's performance. Just wait and see folks!

I heard Syed Mokhtar want to take over source from another forum!

end of downtrend soon!

Dun worry, rally coming up! :) Chinese New Year angpow!

good rebound, this means serious business for CNY!

quite active this morning

coming soon ady prior to Chinese New Year rally!

Rebounce!

yes, buy lower and when up, smiling!

Who dun believe on Hovid never mind, you all will regret!

Ini Kalilah!

Tarik Tali hopefully can close 0.35 today!

Today all play tarik tali! :)

angclg, yes because this stock is stable :)

lee9fold: what to worry? No worry man! :) Dun be so negative, price go back down is an opportunity to buy :) I love this but in fact, it's moving up soon. Buy before it's too late

Today heard BFM that Pharmaceuticals are stock to watch including Hovid for the fiscal year 2014!

a virus link!

No worries, many buyer as well, short term won't drop since everything is positive including the price.

All the best and good luck to us kerengga :)

Terbang! Dun patah balik!

1st TP will target 0.365!

sudah mari!

After sleeping so long, time to fly!

Tocovid SupraBio is currently sold as a dietary supplement. Unlike drugs, dietary supplements cannot make the claim of being able to prevent, treat orcure illnesses due to regulatory restrictions. Hovid is seeking approval from the US FDA to sell Tocovid as a drug that could aid stroke patients. A mid-stageclinical trial on Tocovid will be carried out soon and the company is hopeful ofobtaining approval in the next 3-5 years. Earlier tests have produced strong statistical evidence of the effectiveness of Tocovid in decreasing brain damagecaused by strokes. We gathered that the estimated cost of the clinical trial is around US$3m. Hovid could be sitting on a gold mine if it manages to get FDA approval eventually as there is currently no specific treatment to reduce brain damage in stroke patients. The potential market size for Tocovid is vast.